Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Current Deferred Revenue: 2019-2024

Historic Current Deferred Revenue for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $38.4 million.

  • Nurix Therapeutics' Current Deferred Revenue fell 45.84% to $26.0 million in Q3 2025 from the same period last year, while for Aug 2025 it was $26.0 million, marking a year-over-year decrease of 45.84%. This contributed to the annual value of $38.4 million for FY2024, which is 20.24% down from last year.
  • Latest data reveals that Nurix Therapeutics reported Current Deferred Revenue of $38.4 million as of FY2024, which was down 20.24% from $48.1 million recorded in FY2023.
  • Nurix Therapeutics' 5-year Current Deferred Revenue high stood at $48.1 million for FY2023, and its period low was $32.8 million during FY2020.
  • For the 3-year period, Nurix Therapeutics' Current Deferred Revenue averaged around $41.4 million, with its median value being $38.4 million (2024).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first spiked by 241.23% in 2020, then declined by 20.24% in 2024.
  • Over the past 5 years, Nurix Therapeutics' Current Deferred Revenue (Yearly) stood at $32.8 million in 2020, then climbed by 25.65% to $41.2 million in 2021, then decreased by 8.68% to $37.6 million in 2022, then increased by 27.81% to $48.1 million in 2023, then fell by 20.24% to $38.4 million in 2024.